Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

Profound Medical Corp. ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...

Bayer is successfully executing on an ambitious growth strategyFive pivotal approvals worldwide in 2025 underscore a landmark year of strategic executionBayer will drive significant global regulatory ...

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

While there has been remarkable progress in the number of people surviving with stage 4 cancer, MSK remains dedicated to research that will spur much needed advances.

The latest edition of an annual report finds new cases continue to rise and outcomes have worsened for some cancers.